Detalhe da pesquisa
1.
A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers.
Invest New Drugs
; 40(4): 747-755, 2022 08.
Artigo
Inglês
| MEDLINE | ID: mdl-35404015
2.
NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus.
Int J Cancer
; 136(6): E590-601, 2015 Mar 15.
Artigo
Inglês
| MEDLINE | ID: mdl-25081390
3.
Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma.
Invest New Drugs
; 31(2): 425-34, 2013 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-22864522
4.
Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma.
Cancer Cell
; 41(7): 1222-1241.e7, 2023 07 10.
Artigo
Inglês
| MEDLINE | ID: mdl-37433281
5.
Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination.
Int J Cancer
; 130(3): 584-92, 2012 Feb 01.
Artigo
Inglês
| MEDLINE | ID: mdl-21413013
6.
Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma.
Clin Cancer Res
; 28(12): 2567-2578, 2022 06 13.
Artigo
Inglês
| MEDLINE | ID: mdl-35395080
7.
Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™.
Cancer Immunol Immunother
; 60(11): 1625-37, 2011 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-21698545
8.
A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma.
Oncoimmunology
; 10(1): 1898105, 2021 03 26.
Artigo
Inglês
| MEDLINE | ID: mdl-33796406
9.
Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma.
Clin Cancer Res
; 15(6): 2166-73, 2009 Mar 15.
Artigo
Inglês
| MEDLINE | ID: mdl-19276262
10.
Phase II Study of Arginine Deprivation Therapy With Pegargiminase in Patients With Relapsed Sensitive or Refractory Small-cell Lung Cancer.
Clin Lung Cancer
; 21(6): 527-533, 2020 11.
Artigo
Inglês
| MEDLINE | ID: mdl-32859536
11.
Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma.
J Immunother Cancer
; 8(1)2020 04.
Artigo
Inglês
| MEDLINE | ID: mdl-32317292
12.
A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma.
Clin Cancer Res
; 26(13): 3193-3201, 2020 07 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32205463
13.
Autologous Lymphocyte Infusion Supports Tumor Antigen Vaccine-Induced Immunity in Autologous Stem Cell Transplant for Multiple Myeloma.
Cancer Immunol Res
; 7(4): 658-669, 2019 04.
Artigo
Inglês
| MEDLINE | ID: mdl-30745365
14.
Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-α2b in patients with metastatic melanoma.
Melanoma Res
; 27(4): 342-350, 2017 08.
Artigo
Inglês
| MEDLINE | ID: mdl-28489678
15.
NY-ESO-1 Protein Cancer Vaccine With Poly-ICLC and OK-432: Rapid and Strong Induction of NY-ESO-1-specific Immune Responses by Poly-ICLC.
J Immunother
; 40(4): 140-147, 2017 May.
Artigo
Inglês
| MEDLINE | ID: mdl-28338507
16.
Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer.
J Clin Oncol
; 33(24): 2609-16, 2015 Aug 20.
Artigo
Inglês
| MEDLINE | ID: mdl-26124477
17.
Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma.
Cancer Immunol Res
; 3(3): 278-287, 2015 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-25633712
18.
Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.
J Immunother
; 37(2): 84-92, 2014.
Artigo
Inglês
| MEDLINE | ID: mdl-24509171
19.
Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients.
Clin Cancer Res
; 18(23): 6497-508, 2012 Dec 01.
Artigo
Inglês
| MEDLINE | ID: mdl-23032745
20.
Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant.
J Immunol
; 181(1): 776-84, 2008 Jul 01.
Artigo
Inglês
| MEDLINE | ID: mdl-18566444